ES2485040T3 - Inhibidores de cinasa de adhesión focal - Google Patents

Inhibidores de cinasa de adhesión focal Download PDF

Info

Publication number
ES2485040T3
ES2485040T3 ES08726698.7T ES08726698T ES2485040T3 ES 2485040 T3 ES2485040 T3 ES 2485040T3 ES 08726698 T ES08726698 T ES 08726698T ES 2485040 T3 ES2485040 T3 ES 2485040T3
Authority
ES
Spain
Prior art keywords
alkyl
substituted
alkoxy
roc
mono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08726698.7T
Other languages
English (en)
Spanish (es)
Inventor
Congxin Liang
Marcel Koenig
Yuanjun He
Pär Holmberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Application granted granted Critical
Publication of ES2485040T3 publication Critical patent/ES2485040T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES08726698.7T 2007-03-16 2008-03-10 Inhibidores de cinasa de adhesión focal Active ES2485040T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US89537907P 2007-03-16 2007-03-16
US895379P 2007-03-16
US94663707P 2007-06-27 2007-06-27
US946637P 2007-06-27
US3002508P 2008-02-20 2008-02-20
US30025 2008-02-20
PCT/US2008/003205 WO2008115369A2 (en) 2007-03-16 2008-03-10 Inhibitors of focal adhesion kinase

Publications (1)

Publication Number Publication Date
ES2485040T3 true ES2485040T3 (es) 2014-08-12

Family

ID=39628767

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08726698.7T Active ES2485040T3 (es) 2007-03-16 2008-03-10 Inhibidores de cinasa de adhesión focal

Country Status (10)

Country Link
US (2) US8501763B2 (enExample)
EP (2) EP2727909A1 (enExample)
JP (2) JP5569956B2 (enExample)
CN (2) CN101679264A (enExample)
CA (1) CA2681015C (enExample)
DK (1) DK2134689T3 (enExample)
ES (1) ES2485040T3 (enExample)
PL (1) PL2134689T3 (enExample)
TW (2) TW201618780A (enExample)
WO (1) WO2008115369A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501763B2 (en) 2007-03-16 2013-08-06 The Scripps Research Institute Inhibitors of focal adhesion kinase
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP2011512413A (ja) * 2008-02-19 2011-04-21 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｆａｋの阻害剤としてのアニリノピリジン
JP5551689B2 (ja) * 2008-06-17 2014-07-16 アストラゼネカ アクチボラグ ピリジン化合物
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
JP2012511567A (ja) * 2008-12-10 2012-05-24 ドン ファ ファーム カンパニー リミテッド 新規の２，６−置換−３−ニトロピリジン誘導体、その製造方法及びこれを含む薬学組成物
US20120196858A1 (en) * 2009-08-12 2012-08-02 Poniard Pharmaceuticals ,Inc. Method of promoting apoptosis and inhibiting metastasis
AU2011254550B2 (en) 2010-05-21 2013-11-07 Noviga Research Ab Novel pyrimidine derivatives
MX340819B (es) * 2010-06-29 2016-07-26 Poniard Pharmaceuticals Inc * Formulacion oral de inhibidores de quinasa.
CN103168037A (zh) * 2010-06-30 2013-06-19 博尼亚德医药品股份有限公司 激酶抑制剂的合成和用途
DE102010034699A1 (de) 2010-08-18 2012-02-23 Merck Patent Gmbh Pyrimidinderivate
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
CA2825790A1 (en) * 2011-01-26 2012-08-02 Board Of Regents The University Of Texas System Combinations
AU2012216893B2 (en) 2011-02-17 2016-08-11 Cancer Therapeutics Crc Pty Limited FAK inhibitors
CN103534240B (zh) 2011-02-17 2015-12-09 癌症疗法Crc私人有限公司 选择性fak抑制剂
EP2688883B1 (en) 2011-03-24 2016-05-18 Noviga Research AB Pyrimidine derivatives
DE102011111400A1 (de) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
JP6073910B2 (ja) 2011-11-09 2017-02-01 キャンサー・リサーチ・テクノロジー・リミテッド ５−（ピリジン−２−イル−アミノ）−ピラジン−２−カルボニトリル化合物及びその治療使用
KR102341637B1 (ko) 2012-05-15 2021-12-21 캔써 리서치 테크놀로지 리미티드 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도
HK1209742A1 (en) 2012-11-20 2016-04-08 沃泰克斯药物股份有限公司 Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
CN105164114B (zh) * 2013-05-01 2018-03-23 豪夫迈·罗氏有限公司 C‑连接的杂环烷基取代的嘧啶类和它们的用途
WO2015035199A1 (en) * 2013-09-06 2015-03-12 Mayo Foundation For Medical Education And Research Neem compositions used for the treatment of cancer
WO2015054477A1 (en) 2013-10-09 2015-04-16 The General Hospital Corporation Methods of diagnosing and treating b cell acute lymphoblastic leukemia
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
AU2016286091B2 (en) 2015-06-29 2021-02-04 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
SG11201803242TA (en) 2015-10-29 2018-05-30 Effector Therapeutics Inc Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2
CN108602814A (zh) 2015-10-29 2018-09-28 效应治疗股份有限公司 抑制mnk1和mnk2的吡咯并-、吡唑并-、咪唑并-嘧啶和吡啶化合物
WO2017087808A1 (en) 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
ES2829052T3 (es) 2015-11-26 2021-05-28 Novartis Ag Derivados de diaminopiridina
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
JP2020507588A (ja) 2017-02-14 2020-03-12 イーフェクター セラピューティクス， インコーポレイテッド ピぺリジン置換ＭｎＫ阻害剤およびそれに関連する方法
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
AU2019236402A1 (en) 2018-03-12 2020-10-01 Assistance Publique-Hôpitaux De Paris (Aphp) Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
US20220040317A1 (en) * 2018-09-27 2022-02-10 Dana-Farber Cancer Institute, Inc. Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use
BR112021007745A2 (pt) 2018-10-24 2021-07-27 Effector Therapeutics, Inc. formas cristalinas de inibidores de mnk
CN110724137B (zh) * 2019-11-13 2021-03-30 广东工业大学 一种噻吩类衍生物及其制备方法与应用
CN111233834B (zh) * 2020-03-09 2021-08-31 北京师范大学 一类靶向fak的化合物和其标记物、及它们的制备方法和应用
WO2021237121A1 (en) * 2020-05-21 2021-11-25 Gossamer Bio Services, Inc. Substituted pyridines
CN114181257B (zh) * 2020-09-14 2025-02-14 四川科伦博泰生物医药股份有限公司 吡啶类化合物，包含其的药物组合物，其制备方法及其用途
EP4263523A2 (en) * 2020-12-16 2023-10-25 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
GB202113079D0 (en) * 2021-09-14 2021-10-27 Ucl Business Ltd New therapy
WO2023218245A1 (en) * 2022-05-13 2023-11-16 Voronoi Inc. Heteroaryl derivative compounds, and pharmaceutical composition comprising thereof
WO2024251270A1 (zh) * 2023-06-08 2024-12-12 希格生科（深圳）有限公司 含氮芳环化合物及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100521735B1 (ko) * 2000-02-25 2005-10-17 에프. 호프만-라 로슈 아게 아데노신 수용체 조절인자
GB0004888D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds
TW200409629A (en) * 2002-06-27 2004-06-16 Bristol Myers Squibb Co 2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors
US7585866B2 (en) * 2002-07-31 2009-09-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
AR063527A1 (es) 2006-10-23 2009-01-28 Cephalon Inc Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores de alk y c-met
CN103641816A (zh) 2006-12-08 2014-03-19 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
CN101616895A (zh) 2006-12-08 2009-12-30 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
US8501763B2 (en) 2007-03-16 2013-08-06 The Scripps Research Institute Inhibitors of focal adhesion kinase
JP2011512413A (ja) 2008-02-19 2011-04-21 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｆａｋの阻害剤としてのアニリノピリジン

Also Published As

Publication number Publication date
CA2681015C (en) 2016-06-21
WO2008115369A3 (en) 2008-11-13
US20130281443A1 (en) 2013-10-24
US20110046121A1 (en) 2011-02-24
EP2134689A2 (en) 2009-12-23
EP2134689B1 (en) 2014-04-23
PL2134689T3 (pl) 2014-10-31
US9580439B2 (en) 2017-02-28
DK2134689T3 (da) 2014-06-30
TW201618780A (zh) 2016-06-01
WO2008115369A2 (en) 2008-09-25
JP5569956B2 (ja) 2014-08-13
CN103588704A (zh) 2014-02-19
JP2014148542A (ja) 2014-08-21
TWI536991B (zh) 2016-06-11
TW200901996A (en) 2009-01-16
CN101679264A (zh) 2010-03-24
CA2681015A1 (en) 2008-09-25
EP2727909A1 (en) 2014-05-07
US8501763B2 (en) 2013-08-06
JP2010521458A (ja) 2010-06-24
CN103588704B (zh) 2016-09-14

Similar Documents

Publication Publication Date Title
ES2485040T3 (es) Inhibidores de cinasa de adhesión focal
MX2017002241A (es) Compuestos de aminopirimidina como inhibidores de jak.
AR076550A1 (es) Inhibidores de la janus tirosina kinasa (jak)
AR059036A1 (es) Compuestos para el tratamiento de trastornos inflamatorios
AR074426A1 (es) Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
GT200800211A (es) Derivados de dihidropirazolopirimidinona
AR080032A1 (es) Compuestos de pirazol como antagonistas de crth2
PE20231190A1 (es) Degradadores de moleculas pequenas de piperidinilo de helios y procedimientos de uso
SV2016005312A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cã�ncer
WO2009010789A3 (en) Pyrimidine derivatives 934
CO6241157A2 (es) "derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9"
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
AR053577A1 (es) Piperazin-benzotiofenos sustituidos para el tratamiento de desordenes mentales
AR068813A1 (es) Derivados de pirazol sustituidos como antagonistas del receptor de androgenos (ar), un agente farmaceutico que los comprende y su uso en el tratamiento del cancer de prostata
AR077328A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
AR080785A1 (es) Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros.
PE20070855A1 (es) Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
WO2009043320A3 (en) Substituted 6-(alkylbenzylamino)purine derivatives for use as cytokinin receptor antagonists and preparations containing these derivatives
CO5640117A2 (es) Derivados de 2,4-diamonopirimidina
MXPA05007352A (es) Compuestos triciclicos inhibidores de proteina quinasa para mejorar la eficacia de agentes antineoplasicos y terapia de radiacion.
AR062110A1 (es) Derivado de anillo fusionado de espiroquetas y su uso como farmaco antidiabetico
WO2008007123A3 (en) Pharmaceutical compounds
CR10722A (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3
UY30577A1 (es) Derivados de éter diarilico y usos de los mismos